Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
Acorda Therapeutics announces Hatch-Waxman extension of AMPYRA® (dalfampridine) sustained-release formulation patent
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Biogen Idec receives notification of PDUFA date extension
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Epigenetics of Multiple Sclerosis: An Updated Review.
Artesunate Ameliorates Experimental Autoimmune Encephalomyelitis by Inhibiting Leukocyte Migration to the Central Nervous System.
Fatigue and Comorbidities in Multiple Sclerosis.
The Correlation between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of Patients with Multiple Sclerosis.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism.
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.
Influence of infection on exacerbations of multiple sclerosis.
The use of hematopoietic stem cells in autoimmune diseases.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
Overview of the immune system.
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.

Pages